Targanta Therapeutics Corporation (Nasdaq: TARG) today announced that oritavancin, the Company's investigational antibiotic therapy for the treatment of complicated skin ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE